Skip to content

Skin Safety Study on Healthy Human Subjects

Evaluation of dermatological safety of investigational products by 24hrs patch test under complete occlusion on healthy human subjects

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007849
Enrollment
24
Registered
2017-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1.Dabur Gulabari Premium Gulab Jal(036/P136) 2.Dabur Gulabari Premium Gulab Jal(036/P137) 3.Gulabari Rose Glow Lotion 4.Dadur Gulabari Moisturising cold cream 5.Gulabari Rose Glow Face

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects in age group 18 - 55 years (both the ages inclusive) 2.Healthy male & female subjects. 3.Subjects with normal Fitzpatrick skin type III to V. 4.Subjects willing to give a voluntary written informed consent. 5.Subjects willing to maintain the patch test in position for 24 hours. 6.Subject having not participated in a similar investigation in the past two weeks. 7.Subjects willing to come for regular follow up visits. 8.Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: 1.Infection, allergy on the tested area. 2.Skin allergy antecedents or atopic subjects. 3.Athletes and subjects with history of excessive sweating. 4.Cutaneous disease which may influence the study result. 5.Subjects on oral corticosteroid. 6.Subjects participating in any other cosmetic or therapeutic study. 7.Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

Design outcomes

Primary

MeasureTime frame
Evaluation of dermatological safety of investigational products by 24 hours patch test under complete occlusion on healthy human subjects with normal skinTimepoint: 0 hr, 24 hr, 7 days

Secondary

MeasureTime frame
Overall safety of SubjectsTimepoint: 0 hr, 24 hr, 7 days

Countries

India

Contacts

Public ContactDr Mukesh Ramnane

Dabur India Limited

arun.gupta@dabur.com01203378614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026